Clinical Trials on Malignant Glioma in Hong Kong

Total 115 results

Chinese University of Hong Kong

Recruiting

EUS-guided Hepatico-gastrostomy Using a Novel Lumen Apposing Metal Stent

Malignant Biliary Obstruction

Hong Kong
Chinese University of Hong Kong

Not yet recruiting

EUS-guided Hepatico-gastrostomy With Hot Giobor

Malignant Biliary Obstruction

Hong Kong
Center Trials & Treatment

Withdrawn

Clinical Trial of the Use of the Nasal Spray of Patients With Recurrence of Glioblastoma

Gliosarcoma | Recurrent Glioblastoma | Anaplastic Gliomas

Singapore, Hong Kong
The University of Hong Kong

Completed

Effectiveness of an Integrated Programme in Promoting the Regular Physical Activity Among Childhood Cancer Survivors

Malignant Childhood Neoplasm

China
The University of Hong Kong
Queen Elizabeth Hospital, Hong Kong; Prince of Wales Hospital, Shatin, Hong... and other collaborators

Unknown

Activity Behaviours in Patients With Malignant Pleural Effusion

Malignant Pleural Effusion

Hong Kong
The University of Hong Kong

Recruiting

Talazoparib - Carboplatin for Recurrent High-grade Glioma With DDRd (TAC-GReD)

Recurrent Glioblastoma | Recurrent Glioma | Poly ADP Ribose Polymerase (PARP) Inhibitor | PTEN Gene Inactivation | IDH Mutation

Hong Kong
Chinese University of Hong Kong

Terminated

Irreversible Electroporation for Inoperable Hepatic and Pancreatic Malignancy (IRE)

Pancreatic Cancer | Hepatic Malignant Tumors

Hong Kong
Chinese University of Hong Kong

Recruiting

Primary Percutaneous Pericardiotomy for Malignant Pericardial Effusion (PMAP) (PMAP)

Pericardial Effusion Malignant

Hong Kong
Organisation for Oncology and Translational Research

Unknown

Exemestane Plus Everolimus for Hormone-receptor Positive Metastatic Breast Cancer

Hormone Receptor Positive Malignant Neoplasm of Breast

China
The University of Hong Kong

Recruiting

Comparing Different Sizes of Small-bore Chest Drains in Malignant Pleural Effusion

Pleural Effusion, Malignant | Lung Cancer Stage IV | Chest Tubes

Hong Kong
The University of Hong Kong

Completed

Prognostic Factors on Malignant Pleural Effusion

Lung Cancer | Pleural Effusion, Malignant

Hong Kong
The University of Hong Kong

Not yet recruiting

Endoscopic Ultrasound Guided Coeliac Plexus Neurolysis for Cancer Pain

Pain Management | Malignancy

Hong Kong
Chinese University of Hong Kong
National University Hospital, Singapore; Singapore General Hospital; Changi General... and other collaborators

Completed

Partially Covered Versus Uncovered Pyloro-duodenal Stents for Unresectable Malignant Gastric Outlet Obstruction. A Double Blinded Randomised Controlled Trial.

Unresectable Malignant Gastric Outlet Obstruction

China
Hong Kong Children's Hospital
The University of Hong Kong

Recruiting

Propofol vs Sevo for Paediatric Tumor Surgery

Carcinoma | Cancer | Solid Tumor | Malignancy

Hong Kong
The University of Hong Kong

Recruiting

oGVHD After Bone Marrow Transplantation: a Territory-wide Cohort

Cancer | Graft Vs Host Disease | Haematological Malignancy

Hong Kong
Chinese University of Hong Kong

Terminated

EUS-guided CGN for Inoperable Cancer

Intractable Abdominal Pain Secondary to Inoperable Malignancy

China
Chinese University of Hong Kong
Roche Diagnostics

Recruiting

Comparing N-terminal-proB-type Natriuretic Peptide With Other Criteria in Pleural Fluid Analysis

Heart Failure | Infections | Renal Failure | Cirrhosis | Fluid Overload | Pleural Effusion | Malignant Neoplasm | Hypoalbuminemia

Hong Kong
Center Trials & Treatment

No longer available

Expanded Access for Pembrolizumab (MK-3475)

Glioblastoma Multiforme | Melanoma (Skin) | Melanoma Recurrent | Glioma of Brain | Glioblastoma by Gene Expression Profile

Hong Kong, Belarus, Tajikistan, Uzbekistan
Chinese University of Hong Kong
Tokyo Medical University; Kinki University

Completed

EUS - Guided Choledocho-duodenostomy Versus ERCP With Covered Metallic Stents in Patients With Unresectable Malignant Distal Common Bile Duct Strictures (DRAMBO)

Malignant Biliary Obstruction

Australia, Denmark, China, Japan, Belgium
Novartis Pharmaceuticals

Completed

An East Asian Study of LDE225

Medulloblastoma | Basal Cell Carcinoma | Advanced Solid Tumor Cancers

Taiwan, Hong Kong, Japan
TJ Biopharma Co., Ltd.

Active, not recruiting

A Study to Evaluate the Efficacy and Safety of TJ107 in Lympopenic Patients With Newly Diagnosed Glioblastoma Who Completed Standard Concurrent Chemoradiotherapy (CCRT)

Newly Diagnosed Glioblastoma

China, Hong Kong
Pfizer

Terminated

Study Of Bosutinib With Capecitabine In Solid Tumors And Locally Advanced Or Metastatic Breast Cancer

Advanced Breast Cancer (Parts 1 and 2) | Advanced Pancreatic Cancer (Part 1) | Advanced Colorectal Cancer (Part 1) | Advanced Cholangiocarcinoma (Part 1) | Advanced Glioblastoma Multiforme (Part 1)

United States, Spain, Hong Kong, Belgium, Australia, France
Kyoto Breast Cancer Research Network
Pfizer

Completed

Neoadjuvant Hormonal Therapy Plus Palbociclib in Operable, Hormone Sensitive and HER2-Negative Primary Breast Cancer

Hormone Receptor Positive Malignant Neoplasm of Breast | Breast Cancer Female

Taiwan, Japan, Korea, Republic of, Australia, Hong Kong
Incheon St.Mary's Hospital
National Cancer Center, Korea

Unknown

Procarbazine and Lomustine in Recurrent Glioblastoma

Recurrent Glioblastoma Multiforme

Korea, Republic of
Puma Biotechnology, Inc.

Completed

A Phase 1/2 Study of HKI-272 (Neratinib) in Combination With Paclitaxel (Taxol) in Subjects With Solid Tumors and Breast Cancer

Breast Neoplasms | Advanced Breast Cancer | Advanced Malignant Solid Tumors

United States, Belgium, China, Hong Kong, Canada, Korea, Republic of, India, Poland, Ukraine
Puma Biotechnology, Inc.

Completed

Study Evaluating Neratinib (HKI-272) In Combination With Vinorelbine In Subjects With Solid Tumors And Metastatic Breast Cancer

Breast Cancer | Advanced Malignant Solid Tumors

United States, Taiwan, United Kingdom, Hong Kong, Belgium, France, Spain, China, Netherlands, Poland, Sweden
Novartis Pharmaceuticals

Recruiting

A Study of Safety and Efficacy of KFA115 Alone and in Combination With Pembrolizumab in Patients With Select Advanced Cancers

Carcinoma, Renal Cell | Carcinoma, Non-Small-Cell Lung | Nasopharyngeal Carcinoma | Carcinoma, Ovarian Epithelial | Mesothelioma | Squamous Cell Carcinoma of Head and Neck | Triple Negative Breast Neoplasms | Anal Cancer | Cutaneous Melanoma | Esophagogastric Cancer | Carcinoma, Thymic | High Microsatellite...

Italy, Spain, Singapore, Taiwan, Japan, Germany, Canada, Hong Kong, United States
National Cancer Institute (NCI)

Active, not recruiting

Veliparib, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Malignant Glioma Without H3 K27M or BRAFV600 Mutations

Glioblastoma | Malignant Glioma | Anaplastic Astrocytoma

United States, Canada, Puerto Rico, Australia, New Zealand
National Cancer Institute (NCI)

Recruiting

Dabrafenib Combined With Trametinib After Radiation Therapy in Treating Patients With Newly-Diagnosed High-Grade Glioma

Glioblastoma | Malignant Glioma | Anaplastic Astrocytoma | Anaplastic Astrocytoma, Not Otherwise Specified | Anaplastic Ganglioglioma | Anaplastic Pleomorphic Xanthoastrocytoma | WHO Grade 3 Glioma

United States, Puerto Rico
National Cancer Institute (NCI)

Suspended

A Study of the Drug Selinexor With Radiation Therapy in Patients With Newly-Diagnosed Diffuse Intrinsic Pontine (DIPG) Glioma and High-Grade Glioma (HGG)

Glioblastoma | Malignant Glioma | Anaplastic Astrocytoma | Anaplastic Astrocytoma, Not Otherwise Specified | Diffuse Intrinsic Pontine Glioma | Diffuse Midline Glioma, H3 K27M-Mutant | Glioblastoma, Not Otherwise Specified

United States, Canada, Australia, New Zealand
BioAtla, Inc.

Recruiting

CAB-AXL-ADC Safety and Efficacy Study in Adult and Adolescent Patients With Sarcoma

Undifferentiated Pleomorphic Sarcoma | Myxofibrosarcoma

United States, Hong Kong, Taiwan
National Cancer Institute (NCI)

Active, not recruiting

Larotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions (A Pediatric MATCH Treatment Trial)

Advanced Malignant Solid Neoplasm | Refractory Malignant Solid Neoplasm | Recurrent Ependymoma | Recurrent Hepatoblastoma | Recurrent Langerhans Cell Histiocytosis | Recurrent Malignant Germ Cell Tumor | Recurrent Malignant Glioma | Recurrent Malignant Solid Neoplasm | Recurrent Medulloblastoma | Recurrent... and other conditions

United States, Puerto Rico
National Cancer Institute (NCI)
Children's Oncology Group

Active, not recruiting

Ivosidenib in Treating Patients With Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With IDH1 Mutations (A Pediatric MATCH Treatment Trial)

Refractory Malignant Solid Neoplasm | Recurrent Ependymoma | Recurrent Ewing Sarcoma | Recurrent Hepatoblastoma | Recurrent Langerhans Cell Histiocytosis | Recurrent Malignant Germ Cell Tumor | Recurrent Malignant Glioma | Recurrent Malignant Solid Neoplasm | Recurrent Medulloblastoma | Recurrent Neuroblastoma and other conditions

United States, Puerto Rico, Australia
National Cancer Institute (NCI)

Active, not recruiting

Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating Alterations in Cell Cycle Genes (A Pediatric MATCH Treatment Trial)

Recurrent Childhood Ependymoma | Advanced Malignant Solid Neoplasm | Recurrent Ewing Sarcoma | Recurrent Hepatoblastoma | Recurrent Langerhans Cell Histiocytosis | Recurrent Malignant Germ Cell Tumor | Recurrent Malignant Glioma | Recurrent Medulloblastoma | Recurrent Neuroblastoma | Recurrent Non-Hodgkin... and other conditions

United States, Puerto Rico
National Cancer Institute (NCI)

Active, not recruiting

Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial)

Malignant Glioma | Recurrent Childhood Ependymoma | Rhabdoid Tumor | Advanced Malignant Solid Neoplasm | Refractory Malignant Solid Neoplasm | Recurrent Hepatoblastoma | Recurrent Langerhans Cell Histiocytosis | Recurrent Malignant Solid Neoplasm | Recurrent Medulloblastoma | Recurrent Neuroblastoma | Recurrent... and other conditions

United States, Puerto Rico
National Cancer Institute (NCI)
Children's Oncology Group

Active, not recruiting

Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial)

Recurrent Hodgkin Lymphoma | Refractory Hodgkin Lymphoma | Rhabdoid Tumor | Advanced Malignant Solid Neoplasm | Refractory Malignant Solid Neoplasm | Ann Arbor Stage III Hodgkin Lymphoma | Ann Arbor Stage IV Hodgkin Lymphoma | Recurrent Ependymoma | Recurrent Ewing Sarcoma | Recurrent Hepatoblastoma | Recurrent... and other conditions

United States, Puerto Rico
National Cancer Institute (NCI)
Children's Oncology Group

Active, not recruiting

Selpercatinib for the Treatment of Advanced Solid Tumors, Lymphomas, or Histiocytic Disorders With Activating RET Gene Alterations, a Pediatric MATCH Treatment Trial

Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Recurrent Ependymoma | Recurrent Ewing Sarcoma | Recurrent Hepatoblastoma | Recurrent Histiocytic and Dendritic Cell Neoplasm | Recurrent Langerhans Cell Histiocytosis | Recurrent Lymphoma | Recurrent Malignant Germ Cell Tumor | Recurrent Malignant... and other conditions

United States, Puerto Rico, Australia
National Cancer Institute (NCI)
Children's Oncology Group

Recruiting

Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial)

Malignant Solid Neoplasm | Advanced Malignant Solid Neoplasm | Refractory Malignant Solid Neoplasm | Recurrent Ependymoma | Recurrent Hepatoblastoma | Recurrent Langerhans Cell Histiocytosis | Recurrent Malignant Germ Cell Tumor | Recurrent Malignant Glioma | Recurrent Malignant Solid Neoplasm | Recurrent... and other conditions

United States, Puerto Rico, Australia
Eli Lilly and Company
Loxo Oncology, Inc.

Active, not recruiting

Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations

Glioma | Cholangiocarcinoma | Chondrosarcoma | Any Solid Tumor

United States, Spain, Korea, Republic of, Australia, Japan, Taiwan, France, Singapore, Hong Kong
National Cancer Institute (NCI)

Active, not recruiting

Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)

Recurrent Childhood Medulloblastoma | Recurrent Childhood Ependymoma | Advanced Malignant Solid Neoplasm | Refractory Malignant Solid Neoplasm | Recurrent Hepatoblastoma | Recurrent Langerhans Cell Histiocytosis | Recurrent Malignant Glioma | Recurrent Malignant Solid Neoplasm | Recurrent Neuroblastoma and other conditions

United States, Puerto Rico
Intuitive Surgical

Active, not recruiting

da Vinci SP® Investigational Device Exemption Study in Colorectal Procedures

Colorectal Cancer | Benign or Malignant Rectal or Colon Tumors

United States, Korea, Republic of
National Cancer Institute (NCI)

Active, not recruiting

Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial

Malignant Solid Neoplasm | Recurrent Melanoma | Recurrent Ependymoma | Recurrent Ewing Sarcoma | Recurrent Hepatoblastoma | Recurrent Langerhans Cell Histiocytosis | Recurrent Malignant Germ Cell Tumor | Recurrent Malignant Glioma | Recurrent Medulloblastoma | Recurrent Neuroblastoma | Recurrent Non-Hodgkin... and other conditions

United States, Puerto Rico
National Cancer Institute (NCI)

Active, not recruiting

Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)

Advanced Malignant Solid Neoplasm | Refractory Malignant Solid Neoplasm | Recurrent Ewing Sarcoma | Recurrent Hepatoblastoma | Recurrent Histiocytic and Dendritic Cell Neoplasm | Recurrent Langerhans Cell Histiocytosis | Recurrent Malignant Germ Cell Tumor | Recurrent Malignant Solid Neoplasm | Recurrent... and other conditions

United States, Puerto Rico
Astellas Pharma Global Development, Inc.
Basilea Pharmaceutica International Ltd

Completed

A Study of Intravenous and Oral Isavuconazonium Sulfate in Pediatric Patients

Hematological Malignancy

United States
National Cancer Institute (NCI)

Recruiting

Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)

Malignant Glioma | Rhabdoid Tumor | Advanced Malignant Solid Neoplasm | Refractory Malignant Solid Neoplasm | Recurrent Ependymoma | Recurrent Ewing Sarcoma | Recurrent Hepatoblastoma | Recurrent Langerhans Cell Histiocytosis | Recurrent Malignant Germ Cell Tumor | Recurrent Malignant Solid Neoplasm | Recurrent... and other conditions

United States, Puerto Rico, Australia, Canada
Children's Oncology Group
National Cancer Institute (NCI)

Recruiting

Neuropsychological and Behavioral Testing in Younger Patients With Cancer

Childhood Malignant Neoplasm

United States, Canada, Puerto Rico, Australia, New Zealand
National Cancer Institute (NCI)

Active, not recruiting

Samotolisib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial)

Malignant Glioma | Rhabdoid Tumor | Advanced Malignant Solid Neoplasm | Refractory Malignant Solid Neoplasm | Recurrent Ependymoma | Recurrent Ewing Sarcoma | Recurrent Hepatoblastoma | Recurrent Langerhans Cell Histiocytosis | Recurrent Malignant Germ Cell Tumor | Recurrent Malignant Solid Neoplasm | Recurrent... and other conditions

United States, Puerto Rico
MedImmune LLC

Completed

Evaluating The Antitumor Activity Of MEDI-522 With Or Without Dacarbazine In Patients With Metastatic Melanoma

Melanoma | Malignant Metastatic Melanoma

United States
Curium US LLC

Active, not recruiting

177Lu-PSMA-I&T for Metastatic Castration-Resistant Prostate Cancer

Metastasis From Malignant Tumor of Prostate

United States, France, Spain, Italy
Children's Oncology Group
National Cancer Institute (NCI); Yale University

Active, not recruiting

Mobile Health and Social Media Physical Activity Intervention Among Adolescent and Young Adult Childhood Cancer Survivors, the StepByStep Study

Hematopoietic and Lymphoid Cell Neoplasm | Malignant Solid Neoplasm

United States, Canada

Clinical Trials on Malignant Glioma in Hong Kong

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in South Africa

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations